Therapeutic vaccines for breast cancer: Has the time finally come?

Eur J Cancer · 2022 · PMC8608270 · PMID 34823982

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

After a phase II trial showed a trend for superior PFS for Adagloxad simolenin (AS)/OBI-821 compared to placebo in patients with Globo-H-high BC, the GLORIA study was initiated [ 101 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.